Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9637224 | 0.89 | LMNA (0.43) | TRPA1LMNAALDH1A1 | |
| SCHEMBL1305172 | 0.80 | TRPA1 (0.45) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9806392 | 0.79 | TRPA1 (0.41) | TRPA1LMNAADRA2CCYP2D6ALDH1A1 | |
| SCHEMBL28806587 | 0.79 | TRPA1 (0.41) | TRPA1LMNAADRA2CCYP2D6ALDH1A1 | |
| SCHEMBL4641824 | 0.78 | TRPA1 (0.44) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL9222442 | 0.78 | TRPA1 (0.64) | TRPA1LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL1334629 | 0.78 | AKR1C3 (0.50) | TRPA1LMNAHPGDCYP2D6SRC | |
| SCHEMBL28233586 | 0.78 | TRPA1 (0.40) | TRPA1LMNAKDM4EALDH1A1 | |
| SCHEMBL1334624 | 0.78 | AKR1C3 (0.50) | TRPA1LMNAHPGDCYP2D6SRC | |
| SCHEMBL563813 | 0.76 | LMNA (0.45) | TRPA1LMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111164106-A | Method for producing polymer latex | 日本瑞翁株式会社 | 2020-05-15 | — | — | CN | disclosed |
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | TRPA1 1840/4885LMNA 4620/4885ADRA2A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.